Abdelaziz Benjouad

Title: Innovations of Abdelaziz Benjouad in HIV Therapy

Introduction

Abdelaziz Benjouad is a notable inventor based in Cachan, France. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic solutions for HIV.

Latest Patents

Benjouad holds a patent for "Multiple branch peptide constructions for use against HIV." This invention focuses on multiple branch peptide constructions (MBPCs) that are formed from a core matrix. These MBPCs are attached to peptides derived from the V3 loop of the envelope glycoprotein of HIV-1. The patent emphasizes the amino acid sequence GPGR (SEQ ID NO: 5), preferably in the form GPGRAF, while ensuring that the peptides are free of the sequences IGPGR (SEQ ID NO: 1) or IXXGPGR (SEQ ID NO: 3). The MBPCs are designed to prevent virus/cell infection and cell-to-cell virus transmission between CD4+ cells and HIV, without hindering the immunogenic role of the CD4+ cells. Furthermore, these constructions are effective in blocking CD4 receptors on lymphocytes and macrophages, as well as GalCer receptors on colon epithelial cells. Importantly, the MBPCs are non-immunogenic and non-toxic at therapeutic doses, making them suitable for clinical use.

Career Highlights

Abdelaziz Benjouad is associated with Armel S.A., where he continues to advance his research and innovations. His work has the potential to significantly impact the treatment of HIV, providing new avenues for therapy.

Collaborations

Benjouad collaborates with notable colleagues such as Jean M Sabatier and Nouara Yahi, contributing to a dynamic research environment focused on innovative solutions for health challenges.

Conclusion

Abdelaziz Benjouad's work exemplifies the intersection of innovation and healthcare, particularly in the fight against HIV. His patented inventions and collaborations highlight the importance of research in developing effective therapies.